The Scientific Basis and Rationale For Early Thrombolytic Therapy

  • Arie Roth
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


There are vast amounts of data that support the use of thrombolytic treatment in evolving acute myocardial infarction, and the evidence to justify early treatment is substantial. In the landmark GISSI trial [1], the administration of streptokinase within the first 3 hours was associated with a remarkable improvement in mortality (12.0% controls vs. 9.2% streptokinase), whereas in those treated within the first hour, mortality was reduced in as much as 47% (15.4% controls vs. 8.2% streptokinase). A similar relation with time was shown in the Second International Study of Infarct Survival (ISIS-2) [2]: Treatment within the first hour resulted in 13.4% mortality with placebo and 8.1% with streptokinase treatment.


Acute Myocardial Infarction Infarct Size Left Ventricular Function Thrombolytic Therapy Thrombolytic Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    GISSI. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 2:871, 1987.Google Scholar
  2. 2.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1:349, 1988.Google Scholar
  3. 3.
    Castaigne AD, Herve C, Duval-Moulin AM, Gaillard M, Dubois-Rande JL, Boesch C, Wolf M, Lellouche D, Jan F, Vernant P, Huguenard P. Prehospital usc ot APSAC: Results of a placebo-controlled study. Am J Cardiol 64:30A, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1:203, 1988. [Published erratum appears in Lancet 27:519, 1988.]Google Scholar
  5. 5.
    White HD, Norris RM, Brown MA, Takayama Morimasa, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 317:850, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Ritchie JL, Davis KB, Williams DL, Caldwell J, Kennedy JW. Global and regional left ventricular function and tomographic radionuclide perfusion: The western Washington intravenous streptokinase in myocardial infarction trial. Circulation 70:867, 1984.PubMedGoogle Scholar
  7. 7.
    Reimer KA, Lowe JF., Rasmussen MM, Jennings RB. The wave front phenomenon of ischemia cell death: Myocardial infarct size vs. duration ot coronary occlusion in dogs. Circulation 56:786, 1977.PubMedGoogle Scholar
  8. 8.
    Tennannt R, Wiggers CJ. The effect ot coronary occlusion on myocardial contraction. Am J Physiol 112:351, 1935.Google Scholar
  9. 9.
    Blumgart HL, Gilligan R, Schlesinger MJ. Experimental studies on the effect of temporary occlusion of a coronary artery II. The production of myocardial infarction. Am Heart J 22:374, 1941.CrossRefGoogle Scholar
  10. 10.
    Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief corollary artery occlusion in concious dogs. J Clin Invest 56:978, 1975.PubMedGoogle Scholar
  11. 11.
    Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in dog. Arch Parhol Lab Med 70:68, 1960.Google Scholar
  12. 12.
    Bergmann SR, Fox KAA, Luclbrook PA. Determinants of salvage of jeopardized myocardium after coronary thrombolysis. Cardiol Clin 5:67, 1987.PubMedGoogle Scholar
  13. 13.
    Lavallec M, Cox D, Patrick TA, Vatner SF. Salvage of myocardial function by coronary artery reperfusion 1, 2 antl 3 hours after occlusion in concious dogs. Circ Res 53:235, 1983.Google Scholar
  14. 14.
    Baughman KL, Maroko PR, Vatner SF. Effects of coronary artery reperfusion on myocardial infarct size and survival in conscious dogs. Circulation 63:317, 1981.PubMedGoogle Scholar
  15. 15.
    Popovic AD, Neskovoic AN, Babic R, Obradovic V, Bozinovic L, Marinkovic J, Lee JC, Tan M, Thomas JD. Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Serial echocardiographic follow-up. Circulation 90:800, 1994.PubMedGoogle Scholar
  16. 16.
    Lincoff AM, Topol EJ. Trickle down thrombolysis J Am Coll Cardiol 21:1396, 1993.PubMedGoogle Scholar
  17. 17.
    Anderson JL, Karagounis LA, Becker LC, Sorenson SG, Menlove RL, for the TEAM-3 investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: Ventriculographic, enzymatic, and electrocardiographic evidence from rhe TEAM-3 study. Circularion 87:1829, 1993.Google Scholar
  18. 18.
    Hearse DJ, Maxwell L, Saldanha C, Gavin JB. The myocardial vasculature during ischemia and reperfusion: A target for injury and protection. J Mol Cell Cardiol 25:759, 1993.PubMedCrossRefGoogle Scholar
  19. 19.
    Khaja F, Walton JA, Brymer JF, Lo E, Osterberger L, O’Neill WW, Golfer HT, Weiss R, Lee T, Kurian T, Goldberg D, Pitt B, Goldstein S. Intracoronary fibrinolytic cherapy in acute myocardial infarction. Report of a prospective randomized trial. N Engl J Med 308:1305, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    Reduto LA, Smalling RW, Freund GC, Gould KX. Intracoronary infusion of streptokinase in patients with acute myocardial infarction: Effects of reperfusion on left ventricular performance. Am J Cardiol 48:403, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Wackers FJ, Berger HJ, Weinberg MA, Zaret BL. Spontaneous changes in left ventricular function over the first 24 hours of acute transmural myocardial infarction: Implications for evaluating early therapeutic interventions. Circulation 66:748, 1982.PubMedGoogle Scholar
  22. 22.
    Sheehan FH, Doerr R, Schmidt WG, Bolson EL, Uebis R, von Essen R, Effert S, Dodge HT. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: An important determinant of survival. J Am Coll Cardiol 12:289, 1988.PubMedGoogle Scholar
  23. 23.
    Bourdillon PDV, Broderick TM, Williams ES, Davis C, Dillon JC, Armstrong WF, Fineberg N, Ryan T, Feignbaum H. Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimentional echocardiography. Am J Cardiol 63:641, 1989.PubMedCrossRefGoogle Scholar
  24. 24.
    Schmidt WG, Sheehan FH, von Essen R, Uebis R, Effert S. Evolution of left ventricular function after intracoronary thrombolysis for acute myocardial infarction. Am J Cardiol 6.3:497, 1989.CrossRefGoogle Scholar
  25. 25.
    Grines CL, O’Neill W W, Anselmo BG, Juni JE, Topol EJ. Comparison of left ventricular function and contractile reserve after successful recannalization by thrombolysis versus rescue percutaneous transluminal coronary angioplasry for acute myocardial infarction. Am J Cardiol 62:352, 1988.PubMedCrossRefGoogle Scholar
  26. 26.
    Bergmann SR, Lerch RA, Fox KAA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 73:573, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Koren G, Weiss AT, Hasin Y, Appelbaum D, Welber S, Rozenman Y, Lotan C, Mosseri M, Sapoznikov D, Luria MH, Gotsman M. Prevention of myocardial damage in acute myocardial ischemia by early Treatment with intravenous streptokinase. N Engl J Med 313:1384, 1985.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss AT, Fine DG, Appelbaum D, Welber S, Sapoznikov D, Lotan C, Mosseri M, Hasin Y, Gotsman MS. Prehospital coronary thrombolysis: A new strategy in acute myocardial infarction. Chest 92:124, 1987.PubMedCrossRefGoogle Scholar
  29. 29.
    Villemant D, Barriot P, Riou B, Bodenan P, Brunet F, Noto R, Monsallier JF. Achievement of thrombolysis at home in cases of acute myocardial infarction it [letter]. Lancet 1:228, 1987.PubMedCrossRefGoogle Scholar
  30. 30.
    Belgian Eminase Prehospital Study (BEPS) Cooperative Group. Prehospiral thrombolysis in acute myocardial infarction. The Belgian Eminase Prehospital Srudy (BEPS) Eur Hearr J 12:965, 1991.Google Scholar
  31. 31.
    Roth A, Barbash GI, Hod H, Miller HI, Rath S, Modan M, Har-Zahav Y, Keren Ci, Bassan S, Kaplinsky E, Laniado S. Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. J Am Coll Cardiol 15:9.32, 1990.Google Scholar
  32. 32.
    Schofer J, Buttner J, Geng G, Gutschmidt K, Herden HN, Mathey DG, Moecke HP, Ploster P, Raftopoulo A, Sheehan FH, Voelz P. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiology 66:1429, 1990.CrossRefGoogle Scholar
  33. 33.
    The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med 314:1465, 1986.CrossRefGoogle Scholar
  34. 34.
    Simoons ML, Serruys PW, van den Brand M, Res J, Verbeugt PW, Krauss XH, Remme WJ, Bar F, de Zwaan C van der Laarse, Vermeer F, Lubsen J, for the working group on thrombolytic therapy in acute myocardial infarction of the Netherlands interuniversity cardiology instituite. Early thrombolysis in acute myocardial infarction Limitation of infarct size and improved survival. J Am Coll Cardiol 7717 1986.PubMedGoogle Scholar
  35. 35.
    Van de Werf F.Lessons from the European Cooperative Recombinant Tissue-Type Plasminogen Activator (rt-PA) Versus Placebo Trial. J Am Coll Cardiol 12:14A, 1988.PubMedGoogle Scholar
  36. 36.
    McNeili AJ, Cunningham SR, Flannery DJ, Dalzell GW, Wilson CM, Campbell NP, Khan MM, Patterson GC, Webb SW, Adgey AA. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J 61:316, 1989.CrossRefGoogle Scholar
  37. 37.
    Hermens WT, Willems GM, Nijssen KM, Simoons ML. Effect of thrombolytic treatment delay on myocardial infarct size [letter]. Lancet 340:1297, 1992.PubMedCrossRefGoogle Scholar
  38. 38.
    Mathey DG, Sheehan FH, Schofer J, Dodge HT. Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction J Am Coll Cardiol 6.518, 1985.PubMedGoogle Scholar
  39. 39.
    Linderer T, Schroder R, Arntz R, Heineking ML, Wunderlich W, Kohl K, Forycki F, Henzgen R, Wagner J. Prehospiral thrombolysis: Beneficial effect of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 22:1304, 1993.PubMedGoogle Scholar
  40. 40.
    Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. For the Myocardial Infarction Triage and Intervention Project Group. Prehospital-initiated vs hospital-initiated thrombolytic therapy. JAMA 270:1211, 1993.PubMedCrossRefGoogle Scholar
  41. 41.
    Ritchie JL, Cerqueira M, Maynard C, Davis K, Kennedy JW. Ventricular function and infarct size: The western Washington intravenous streptokinase in myocardial infarction trial. J Am Coll Cardiol 11:689, 1988.PubMedGoogle Scholar
  42. 42.
    Maynard C, Althouse R, Olsufka M, Ritchie JL, Davis KB, Kennedy W. Early versus late hospital arrival for acute myocardial infarction in the Western Washignton Thrombolytic therapy trials. Am J Cardiol 63:1296, 1989.PubMedCrossRefGoogle Scholar
  43. 43.
    Armstrong PW, Baigrie RS, Daly PA, Haq A, Gent M, Roberts RS, Freeman MR, Burns R, Liu P, Morgan CD. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomization trial in acute myocardial infarction. J Am Coll Cardiol 13:1469, 1989.PubMedGoogle Scholar
  44. 44.
    Bassand JP, Cassagnes J, Machecourt J, Lusson JR, Anguenot T, Wolf JE, Maublant J, Bertrand B, Schiele F. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function circulation 84:1107, 1991.Google Scholar
  45. 45.
    Cerqueira MD, Maynard C, Ritchie JL. Radionuclide assessment of infarct size and left ventricular function in clinical trials of thrombolysis. Circulation 84:1100, 1991.Google Scholar
  46. 46.
    Norris RM, White HD. Therapeutic trials in coronary thrombosis should measure left ventricular function as primary end-point of treatment. Lancet 1:104, 1988.PubMedCrossRefGoogle Scholar
  47. 47.
    Schwarz F, Schier G, Katus H, Hofmann M, Manrhey J, Tillmanns H, Mehmel HC, Kubler W. Intracoronary thrombolysis in acute myocatdial infarction: Duration of ischemia as a major determinanr of late results after recanalization. Am J Cardiol 50:933, 1982.PubMedCrossRefGoogle Scholar
  48. 48.
    Schroder R, Biamino G, von Leitner ER, Linderer T, Bruggemann T, Heitz J, Vohringer HF, Wegscheider K. Intravenous short-term infusion of streptokinase in acute myocardiial infarction. Circulation 67:536, 1983.PubMedGoogle Scholar
  49. 49.
    Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, Bar F, Zwaan C, Krauss XH, Remme WJ, Res J, Verheught FWA, van Domburg R, Lubsen J, Hugenholtz PG, for the working group on thrombolytic therapy in acute myocardial infarction of the Netherlands interuniversity cardiology instituite. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 7:729, 1986.PubMedGoogle Scholar
  50. 50.
    Rogers WJ, Hood WP, Mantle JA, Baxley WA, Kirklin JK, Zorn GL, Nath HP. Return of left ventricular function after reperfusion in patients with myocardial infarction: Importance of subtotal stenosis or collaterals. J Am Coll Cardiol 69:338, 1984.Google Scholar
  51. 51.
    Marzoll U, Kleiman NS, Dunn JK, Verani MS, Minor ST, Roberts R, Raizner AE. Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: Primacy of baseline ejection fraction. J Am Coll Cardiol 17:613, 1991.PubMedGoogle Scholar
  52. 52.
    Topol EJ, Bates ER, Walton Jr. JA, Baumann G, Wolfe S, Maino J, Bayer L, Gorman L, Kline EM, O’Neill WW, Pitt B. Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: Improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol 10:1173, 1987.PubMedGoogle Scholar
  53. 53.
    Fine DG, Weiss AT, Sapoznikov D, Weiber S, Applebaum D, Lotan C, Hasin Y, Ben-David Y, Koren G, Gotsman MS. Importance of early initiation of intravenous streptokinase therapy for acute myocardial infarction. Am J Cardiol 58:411, 1986.PubMedCrossRefGoogle Scholar
  54. 54.
    Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gortlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherry JT, Bush DE, Chew PH, Gottlieb SH, Halperin HR, Ouyang P, Walford GD, Beli WR, Fatterpaker AK, Llwellyn M, Topol EJ, Healy B, Siu CO, Becker LC, Weisfeld ML. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 317:1613, 1987.PubMedCrossRefGoogle Scholar
  55. 55.
    Van de Werf F, Arnold AE. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 297:1374, 1988.Google Scholar
  56. 56.
    O’Rourke M, Baron D, Keogh A, Kelly R, Nelson G, Barnes C, Raftos J, Graham K, Hillman K, Newman H, Healy J, Woolridge J, Rivers J, White H, Whitlock R, Norris R. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 77:1311, 1988.PubMedGoogle Scholar
  57. 57.
    Kennedy JW, Martin GV, Davis KB, Maynard C, Stadius M, Sheehan FH, Ritchie JL. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial [Published erratum appears in Circulation 77:1037, 1988.] Circulation 77:345, 1988.PubMedGoogle Scholar
  58. 58.
    Bassand JP, Machecourt J, Cassagnes J, Anquenot T, Lusson R, Borel E, Peycelon P, Wolf E, Ducellier D. Multicentric trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Effects on size and left ventricular function. J Am Coll Cardiol 13:988, 1989.PubMedGoogle Scholar
  59. 59.
    Barbash GI, Roth A, Hod H, Miller H, Modan M, Rath S, Har-Zahav Y, Shachar A, Basan S, Batler A, Rabinowitz B, Kaplinsky E, Seligsohn U, Laniado S. Improved survival but not left ventricular function with early and pre-hospitsal treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66:261, 1990.PubMedCrossRefGoogle Scholar
  60. 60.
    Sheehan FH. Left ventricular dysfunction in acute myocardial infarction due to isolated left circumflex coronary artery stenosis. Am J Cardiol 64:440, 1989.PubMedCrossRefGoogle Scholar
  61. 61.
    The TIMI Research Group. Immediate vs. delayed catheterization and angiography following thrombolytic therapy for acute myocardial infarction. TIMI llA results. JAMA 260:2849, 1988.CrossRefGoogle Scholar
  62. 62.
    White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Noris RM. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 320:817, 1989.PubMedCrossRefGoogle Scholar
  63. 63.
    Sheehan FH, Mathey DG, Schofer J, Krebber HJ, Dodge HT. Effect of interventions in salvaging left ventricular function in acute myocardial infarction: A study of intracoronary streptokinase. Am J Cardiol 52:431, 1983.PubMedCrossRefGoogle Scholar
  64. 64.
    Stack RS, Phillips HR, Grierson DS, Behar VS, Kong Y, Peter RH, Swain JL, Greenfield JC Jr. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest 72:84, 1983.PubMedGoogle Scholar
  65. 65.
    Rawles JM, Metcalf MJ, Shirreffs C, Jennings K, Kenmure ACE. Association of patient delay with symptoms, cardiac enzymes, and outcome in acute myocardial infarction. Eur Heart J 11:643, 1990.PubMedGoogle Scholar
  66. 66.
    Willems JL, Wilems RJ, Willems GM. Arnold AE, Van de Werf F, Verstraete M for the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Significance of initial ST segment elevation and depression for management of thrombolytic therapy in acute myocardial infarction. Circulation 82:1147, 1990.PubMedGoogle Scholar
  67. 67.
    Schroder R, Linderer T, Briggemann T, Neuhaus KL, Tebbe U, Wegscheider K. Controversial indications. Rational for thrombolysis: Later than 4–6 h from symptom onset, and in patients with smaller myocardial infarction. Eur Heart J 11:19, 1990.PubMedGoogle Scholar
  68. 68.
    Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 82:1847, 1990.PubMedGoogle Scholar
  69. 69.
    Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1:1367, 1989.PubMedGoogle Scholar
  70. 70.
    Schmidt SB, Borsch MA. The prehospital phase of acute myocardial infarction in the era of thrombolysis. Am J Cardiol 65:1411, 1990.PubMedCrossRefGoogle Scholar
  71. 71.
    Maggioni AP, Maseri A, Fresco C, Franzosi MG, Mauri F, Santoro E, Tognoni G on behalf of GISSI-2. Age related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 329:1442, 1993.PubMedCrossRefGoogle Scholar
  72. 72.
    Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 82:1510, 1990.PubMedGoogle Scholar
  73. 73.
    Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials over 1000 patients. Lancet 343:311, 1994.Google Scholar
  74. 74.
    The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673, 1993.CrossRefGoogle Scholar
  75. 75.
    Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N Engl J Med 329:383, 1993.CrossRefGoogle Scholar
  76. 76.
    Sheehan FH. Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 9:937, 1987.PubMedGoogle Scholar
  77. 77.
    Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 66:1146, 1982.PubMedGoogle Scholar
  78. 78.
    Kloner RA, Przyklenk K, Petel B. Altered myocardial status. The stunned and hibernating myocardium. Am J Med 86:14A, 1989.CrossRefGoogle Scholar
  79. 79.
    Sheehan FH, Thery C, Durand P, Bertrand ME, Bolson EL. Early beneficial effect of streptokinase on left ventricular function in acute myocardial infarction. Am J Cardiol 67:555, 1991.PubMedCrossRefGoogle Scholar
  80. 80.
    Henzlova MJ, Bourge RC, Papaietro SE, Maske LE, Morgan TE, Tauxe L, Rogers WJ. Long-term effect of thrombolytic therapy on left ventricular ejection fraction after acute myocardial infarction. Am J Cardiol 67:1354, 1991.PubMedCrossRefGoogle Scholar
  81. 81.
    Pfisterer M, Zuber M, Wenzel R, Burkart F. Prolonged myocardial stunning after thrombolysis: Can left ventricular function be assessed definitely at hospital discharge? Eur Heart J 12:214, 1991.PubMedGoogle Scholar
  82. 82.
    Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streprokinase from the Thrombolysis in Myocardial Infarcrion (TIMI Phase I) trial. Circulation 755:817, 1987.Google Scholar
  83. 83.
    Jeremy RW, Allman KC, Bautovitch G, Harris PJ. Patterns of left ventricular dilatation during the six months after myocardial infarction. J Am Coll Cardiol 13:304, 1989.PubMedGoogle Scholar
  84. 84.
    Seals AA, Pratt CM, Mahmarian JJ, Tadros S, Kleiman N, Roberts R, Verani MS. Relation of left ventricular dilation during acute myocardial infarction to systolic performance, diastolic dysfunction, infarct size and location. Am J Cardiol 61:224, 1988.PubMedCrossRefGoogle Scholar
  85. 85.
    McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Comep C, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion. Circulation 74:693, 1986.PubMedGoogle Scholar
  86. 86.
    Warren SE, Royal HD, Markis JE, Grossman W, McKay RG. Time course of left ventricular dilation after myocardial infarction: Influence of infarct-related artery and success of coronary thrombolysis. J Am Coll Cardiol 11:12, 1988.PubMedGoogle Scholar
  87. 87.
    White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44, 1987.PubMedGoogle Scholar
  88. 88.
    Shen WF, Cui LQ, Gong LS, Lesbre JP. Beneficial effect of residual flow to the infarct region on left ventricular volume changes after acute myocardial infarction. Am Heart J 119:525, 1990.PubMedCrossRefGoogle Scholar
  89. 89.
    van der Laarse A, Kerkhof PLM, Vermer F, Serruys PW, Hermes WMT, van der Wall EE, Simoons ML, for the working group on thrombolytic therapy in acute myocardial infarction of the Netherlands interuniversity cardiology instituite. Relation between infarct size and lett ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am J Cardiol 61:1, 1988.PubMedCrossRefGoogle Scholar
  90. 90.
    Rawles JM, on behalf of the GREAT group. Recovery of left ventricular function after acute myocardial infarction: Efficacy of domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial. Cor Art Dis 4:801, 1993.CrossRefGoogle Scholar
  91. 91.
    Mowat DHR, Haites NE, Rawles JM. Aortic blood velocity measurement in healthy adults using a simple ultrasound technique. Cardiovasc Res 17:75, 1983.PubMedGoogle Scholar
  92. 92.
    Haites NE, McLennan FM, Mowat DHR, Rawles JM. Assessment of cardiac output by the Doppler ultrasound technique alone. Br Heart J 53:123, 1985.PubMedCrossRefGoogle Scholar
  93. 93.
    Metcalfe MJ, Rawles JM. Stroke distance in acute myocardial infarction: A simple measurment of left ventricular function. Lancet 1.1371, 1989.PubMedCrossRefGoogle Scholar
  94. 94.
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI-2). A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarcrion. Lancet 336:65, 1990.Google Scholar
  95. 95.
    Christian TF, Behrenbeck T, Gersh BJ, Gibbons RJ. One year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. Am J Cardiol 68:21, 1991.PubMedCrossRefGoogle Scholar
  96. 96.
    Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 312:1073, 1985.PubMedCrossRefGoogle Scholar
  97. 97.
    Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheught F, Krauss AK. Long-term benefit of early thrombolytic therapy in patients with acuce MI. 5-year follow-up of trial conduction by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 14:1609, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Arie Roth

There are no affiliations available

Personalised recommendations